BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
- Mechanism
- Curator reviewed
BZL101 works by eliciting a cancer cell’s innate mechanism of self-suicide or apoptosis. The drug selectively releases Apoptosis Inducing Factor-1 (AIF1) from a cancer cell’s mitochondrial membrane. AIF then moves to the cell’s nucleus, disintegrating the DNA structure, and fragmenting and killing the cancer cell.
- Primary indication
- Investigated for use/treatment in breast cancer.Curator reviewed
- Code names
- BZL101
Resolves to
What you can answer from here — as of October 01, 2026
Which companies are running trials of BZL101, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account